Back
Day Range
$4.32
$4.84
52-Week Range
$0.95
$6.14
Volume
10,099,512
50D / 200D Avg
$4.44
/
$2.54
Prev Close
$4.95
Quick Summary
Price History
Financial Trends
Peer Comparison
vs Healthcare sector median (633 peers)
| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -23.2 | 0.2 |
| P/B | 8.8 | 2.8 |
| ROE % | -66.9 | 3.7 |
| Net Margin % | — | 3.9 |
| Rev Growth 5Y % | — | 9.7 |
| D/E | 0.0 | 0.2 |
Analyst Price Target
Hold
$2.80
-35.9%
Low: $2.40
High: $3.20
Forward EPS
-$0.28
Est. Revenue
36.13M
Earnings Estimates
| Period | EPS Est. | Revenue Est. | Analysts |
|---|---|---|---|
| FY2030 |
$3.65
$3.49 – $3.81
|
575.93M | 1 |
| FY2029 |
$1.85
$1.77 – $1.93
|
321.38M | 1 |
| FY2028 |
$0.00
-$0.25 – $0.30
|
123.63M | 3 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-03-19 | -$0.06 | -$0.05 | +21.0% |
| 2025-11-12 | -$0.06 | -$0.06 | +5.3% |
| 2025-08-12 | -$0.08 | -$0.07 | +16.0% |
| 2025-05-13 | -$0.10 | -$0.07 | +30.0% |
| 2025-03-20 | -$0.11 | -$0.08 | +27.3% |
| 2024-11-13 | -$0.13 | -$0.10 | +23.1% |
| 2024-08-13 | -$0.16 | -$0.13 | +18.8% |
| 2024-05-14 | -$0.16 | -$0.21 | -31.3% |
Insider Trading Activity
14 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 7, 2026 |
Varian John
Director
|
grant | 50,000 | — | — |
| Jan 7, 2026 |
Kalin Katherine Bach
Director
|
grant | 50,000 | — | — |
| Jan 7, 2026 |
Wasman Jane
Director
|
grant | 50,000 | — | — |
| Jan 7, 2026 |
Burns John Thomas
CFO
|
grant | 300,000 | — | — |
| Jan 7, 2026 |
SCHEINBERG DAVID A
Director
|
grant | 50,000 | — | — |
| Jan 7, 2026 |
CICIC DRAGAN
SVP, Chief Development Officer
|
grant | 300,000 | — | — |
| Jan 7, 2026 |
VAN NOSTRAND ROBERT L
Director
|
grant | 50,000 | — | — |
| Dec 3, 2025 |
CICIC DRAGAN
SVP, Chief Development Officer
|
other | 63,800 | $1.50 | $95,700.00 |
| Dec 3, 2025 |
Burns John Thomas
CFO
|
other | 58,592 | $1.50 | $87,888.00 |
| Dec 3, 2025 |
Stergiou Angelos M.
President and CEO
|
other | 187,066 | $1.50 | $280,599.00 |
| Nov 19, 2025 |
Kalin Katherine Bach
Director
|
buy | 63,400 | $1.59 | $100,806.00 |
| Jun 12, 2025 |
VAN NOSTRAND ROBERT L
Director
|
buy | 10,000 | $1.48 | $14,800.00 |
| May 30, 2025 |
Wasman Jane
Director
|
buy | 20,000 | $1.69 | $33,800.00 |
| May 22, 2025 |
Kalin Katherine Bach
Director
|
buy | 20,000 | $1.80 | $36,000.00 |
Dividend History
Yield
0.00%
Payout Ratio
0.00%
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
Key Takeaways
Debt/Equity of 0.01 — conservative balance sheet
Negative free cash flow of -28.39M
PEG of 0.31 suggests growth is underpriced
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-66.88%
ROIC-29.50%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
0.01
Current Ratio10.72
Interest Coverage0.00
Valuation
P/E Ratio
-23.15
Forward P/EN/A
P/B Ratio8.77
EV/EBITDAN/A
Dividend Yield0.00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 0.0 | Net Income (TTM) | -26.86M |
| ROE | -66.88% | ROA | -34.29% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -28.39M |
| ROIC | -29.50% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0.01 | Current Ratio | 10.72 |
| Interest Coverage | 0.00 | ||
| Dividends | |||
| Dividend Yield | 0.00% | Payout Ratio | 0.00% |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -23.15 | Forward P/E | N/A |
| P/B Ratio | 8.77 | P/S Ratio | N/A |
| PEG Ratio | 0.31 | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | 76.23 |
| Forward P/S | 17.21 | Fwd Earnings Yield | N/A |
| FCF Yield | -4.57% | ||
| Market Cap | 621.76M | Enterprise Value | 550.87M |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 1.00M | 7.60M |
| Net Income | -26.86M | -30.88M | -37.34M | -41.30M | -20.70M |
| EPS (Diluted) | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 |
| Gross Profit | 0.0 | 0.0 | 0.0 | 900,000.0 | 7.40M |
| Operating Income | -28.27M | -31.51M | -37.87M | -41.95M | -25.29M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 78.35M | 19.43M | 6.22M | 20.94M | 26.43M |
| Total Liabilities | 7.47M | 9.97M | 14.20M | 16.09M | 6.08M |
| Shareholders' Equity | 70.87M | 9.47M | -7.98M | 4.85M | 20.35M |
| Total Debt | 1.00M | 1.00M | 906,000.0 | 945,000.0 | 808,000.0 |
| Cash & Equivalents | 71.89M | 13.89M | 2.53M | 17.13M | 21.46M |
| Current Assets | 75.21M | 16.33M | 3.17M | 17.76M | 23.04M |
| Current Liabilities | 7.02M | 9.51M | 13.74M | 15.52M | 4.98M |